Impact of Palliative Care on Healthcare Utilization of Seriously Ill Older Adults

姑息治疗对重病老年人医疗保健利用的影响

基本信息

项目摘要

DESCRIPTION (provided by applicant): Background: Heart failure (HF) is a chronic illness typically associated with multiple co-morbidities. Nearly 6 million people have HF, with the incidence approaching 1 in 100 adults over the age of 65. HF is the most common cause of hospitalization among adults over the age of 65 and admission rates for this disease have increased steadily over the last two decades. Even with current therapies, HF patients experience high symptom burden and mortality over the course of a prolonged and unpredictable illness. Symptomatic HF confers a worse prognosis than most cancers, with a one-year mortality of approximately 45 percent. Despite these numbers, less than 10% of patients with HF receive any form of palliative care; as of 2007, less than 12% of hospice admissions were patients with HF. Unlike the growing evidence of the benefits of palliative care for patients with cancer, there is a paucity of data regarding the potential benefit of an early palliative care intervention for older patients with HF. Palliative care has the potential to improe clinical outcomes for older patients facing HF by improving pain and other symptom control, clarifying goals of care, and guiding treatment decisions to meet goals. We hypothesize that these elements will translate into reduced healthcare utilization and cost. Objective: The goal of this proposal is to assess better the effect of palliative care consultation on utilization and coss of older adults with HF. Specific Aim 1: To compare the difference in healthcare utilization, including costs of hospitalization, length of stay, number of days in the intensive care unit (ICU) number of rehospitalizations and hospice enrollment at discharge among older patients with HF who received palliative care and those who received usual care. Specific Aim 2: To determine differences in healthcare utilization (as above) between younger (<65 years), older (65 to 84 years), and the oldest old (>85 years) patients with HF who received palliative care and those who received usual care. Methods: To address these aims, a secondary data analysis will be performed of the Palliative Care Leadership Center's (PCLC) Outcomes database, a unique database of hospital administrative and cost data from 8 geographically and structurally diverse hospitals representing low-, middle, and high-cost markets served by 6 palliative care consultation teams. The dataset includes hospital administrative data of patients aged 18 years or older with lengths of stay from 7 to 30 days between 2002 and 2004 who received palliative care and those who did not. Discussion: Data comparing the healthcare utilization of younger, older, and oldest old patients with HF will guide when palliative care will have the greatest benefit and direct policy efforts to improve quality of care and minimize healthcare cost. The results of this study will inform a future prospective cohort study comparing symptoms, survival and healthcare utilization for hospitalized older adults with HF who receive palliative care consultation with those who do not. This will create a better understanding of the benefits of palliative care to this population - a key first step in improving the quality of care for older adlts with HF. PUBLIC HEALTH RELEVANCE: Because heart failure (HF) is a disease of older adults, with more Medicare dollars spent on the diagnosis and treatment of HF than any other diagnosis, it is critical to gain an understanding of how palliative care can be directed to best care for this population of older patients living with HF. By understanding these differences in healthcare utilization and cost for older patients, an early palliative care consultation can effectively targt the different population segments of older adults and thereby, have significant Medicare implications for improving quality of care and minimizing cost of care.
描述(申请人提供):背景:心力衰竭(HF)是一种慢性疾病,通常与多种并存疾病有关。近600万人患有心力衰竭,发病率接近每100名65岁以上的成年人中就有一人。心力衰竭是65岁以上成年人住院的最常见原因,在过去20年中,这种疾病的住院率稳步上升。即使使用目前的治疗方法,心力衰竭患者在长期和不可预测的疾病过程中也会经历高症状负担和死亡率。与大多数癌症相比,有症状的心衰预后更差,一年死亡率约为45%。尽管有这些数字,只有不到10%的心力衰竭患者接受了任何形式的姑息治疗;截至2007年,只有不到12%的临终关怀住院患者是心力衰竭患者。与越来越多的证据表明姑息治疗对癌症患者的益处不同,关于早期姑息治疗干预对老年心力衰竭患者的潜在好处的数据很少。姑息治疗通过改善疼痛和其他症状控制,明确护理目标,并指导治疗决定以达到目标,有可能改善面临心力衰竭的老年患者的临床结果。我们假设,这些因素将转化为医疗保健利用率和成本的降低。目的:本建议的目的是更好地评估姑息治疗咨询对老年心力衰竭患者的利用率和COSS的影响。具体目标1:比较接受姑息治疗的老年心衰患者和接受常规护理的老年心衰患者在医疗利用方面的差异,包括住院费用、住院时间、在重症监护病房(ICU)的天数、再住院次数和出院时的临终关怀登记人数。具体目标2:确定接受姑息治疗的年轻(65岁)、老年(65岁至84岁)和最年长(85岁)心力衰竭患者与接受常规护理的患者在医疗利用方面的差异(如上)。方法:为了达到这些目标,将对姑息治疗领导中心(PCLC)的结果数据库进行二次数据分析,这是一个独特的数据库,其中包括来自8家地理和结构不同的医院的医院管理和成本数据,这些医院代表着由6个姑息治疗咨询团队服务的低、中、高成本市场。该数据集包括2002年至2004年期间接受姑息治疗的18岁或18岁以上、住院时间从7天到30天的患者以及没有接受姑息治疗的患者的医院管理数据。讨论:比较年轻、老年和老年心力衰竭患者的医疗保健利用情况的数据将指导姑息治疗何时具有最大的益处,并指导政策努力,以提高护理质量和最大限度地降低医疗成本。这项研究的结果将为未来的前瞻性队列研究提供信息,比较接受姑息治疗咨询的住院心力衰竭老年患者和没有接受姑息治疗咨询的患者的症状、存活率和医疗利用情况。这将使人们更好地了解姑息治疗对这一人群的好处--这是改善老年心力衰竭患者护理质量的关键第一步。 公共卫生相关性:由于心力衰竭(HF)是一种老年人的疾病,在诊断和治疗心力衰竭上花费的医疗保险资金比任何其他诊断都多,因此了解如何引导姑息治疗来最好地照顾这群患有心力衰竭的老年患者是至关重要的。通过了解老年患者在医疗利用和成本方面的这些差异,早期姑息护理咨询可以有效地针对不同人群的老年人,从而对提高医疗质量和最大限度地降低医疗成本具有重大的医疗保险意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Laura Pilar Gelfman其他文献

Laura Pilar Gelfman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Laura Pilar Gelfman', 18)}}的其他基金

TIER-PALLIATIVE CARE: A population-based care delivery model to match evolving patient needs and palliative care services for community-based patients with heart failure or cancer
分级姑息治疗:基于人群的护理提供模式,以满足不断变化的患者需求,并为社区心力衰竭或癌症患者提供姑息治疗服务
  • 批准号:
    10880994
  • 财政年份:
    2023
  • 资助金额:
    $ 8.48万
  • 项目类别:
Goals of Care Discussions in Older Adults with Heart Failure and Their Caregivers
患有心力衰竭的老年人及其护理人员的护理讨论目标
  • 批准号:
    9033560
  • 财政年份:
    2016
  • 资助金额:
    $ 8.48万
  • 项目类别:
Goals of Care Discussions in Older Adults with Heart Failure and Their Caregivers
患有心力衰竭的老年人及其护理人员的护理讨论目标
  • 批准号:
    10599605
  • 财政年份:
    2016
  • 资助金额:
    $ 8.48万
  • 项目类别:
Goals of Care Discussions in Older Adults with Heart Failure and Their Caregivers
患有心力衰竭的老年人及其护理人员的护理讨论目标
  • 批准号:
    9269956
  • 财政年份:
    2016
  • 资助金额:
    $ 8.48万
  • 项目类别:
Impact of Palliative Care on Healthcare Utilization of Seriously Ill Older Adults
姑息治疗对重病老年人医疗保健利用的影响
  • 批准号:
    8516950
  • 财政年份:
    2012
  • 资助金额:
    $ 8.48万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.48万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了